FDA Pipeline Preview, February 2008

News
Article

FDA-related information through February 2008 on Fluvoxamine extended-release capsules, dalbavancin, bazedoxifene, HPV vaccine (Cervarix), valrubicin, motexafin gadolinium, COL-003, CDX-110, sugammadex, mecaserim rinfabate, A-001, beclomethasone, clobazam, fludarabine tablets, JZP-8, and AST-120

Approvable designations

Complete response letter

Nonapprovable designations

Fast-track designations

Priority review

Orphan drug designations

Recent Videos
Related Content
Rigel Warns Physicians About Fatal Infections from Gavreto

Rigel Warns Physicians About Fatal Infections from Gavreto

Formulary Watch
October 24th 2024
Article

Gavreto used to treat metastatic RET fusion-positive non-small cell lung cancer and RET fusion-positive thyroid cancer.

Read More

© SewcreamStudios - stock.adobe.com

FDA Approves IV Form of Stelara Biosimilar Selardsi

Logan Lutton
October 23rd 2024
Article

This week’s approval expands Seldardsi indications to treat adults with Crohn’s disease and ulcerative colitis.

Read More

freshidea-stock.adobe.com

FDA Approves First-in-Class Drug for Gastric Cancer

Formulary Watch
October 18th 2024
Article

Zolbetuximab — now with the brand name Vyloy — is a monoclonal antibody to treat patients with advanced gastric and gastroesophageal cancers.

Read More

JHVEPhoto-stock.adobe.com

Karen Lynch Steps Down as CEO of CVS Health

Denise Myshko
October 18th 2024
Article

David Joyner has been appointed president and CEO of CVS Health effective immediately.

Read More

luchschenF-stock.abode.com

FDA Approves Imuldosa, the Fifth Stelara Biosimilar

Formulary Watch
October 14th 2024
Article

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

Read More

© Bounpaseuth - stock.adobe.com

FDA Approves Hympavzi for Hemophilia A and B

Logan Lutton
October 11th 2024
Article

Hympavzi is the first anti-tissue factor pathway inhibitor approved in the United States for hemophilia.

Read More

© 2024 MJH Life Sciences

All rights reserved.